U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002216) titled 'BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma' on May 23.
Brief Summary: The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Hodgkin Lymphoma
Advanced Hodgkin Lymphoma
Intervention:
DRUG: Brentu...